Agenus Says Investigational Combination BOT/BAL Now Available To Eligible Patients With Refractory MSS mCRC Under France's Compassionate Access Framework

Author: Benzinga Newsdesk | September 09, 2025 06:45am

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France's compassionate access (Accès compassionnel, or AAC) framework. The French National Agency of Medicines and Health Products Safety's (ANSM) listings for botensilimab and balstilimab are live and detail eligibility (including MSS and no active liver metastases) and dosing. BOT/BAL remains investigational and is not approved for commercial marketing in France or elsewhere.

Posted In: AGEN